Azenta beats estimates and sets fiscal 2027 revenue guidance

By Grace Kim

$167.09 million in fiscal 2026 fourth-quarter revenue and $0.28 in adjusted EPS (earnings per share) put Nasdaq-listed Azenta (AZTA) ahead of analyst expectations on Tuesday, before shares fell 6.7% in Thursday midday trading.

What did the earnings release show?

• Revenue: $167.09 million exceeded the $160.16 million analyst consensus.
• Adjusted EPS: $0.28 beat the $0.11 consensus by $0.17, FiscalAI reported.
• Profitability: Azenta recorded a negative net margin (profit as a share of revenue) of 26.86% and positive return on equity (profit relative to shareholders’ equity) of 1.37%.

The results helped fuel investor enthusiasm as management prepared its fiscal 2027 outlook.

Takeaway: The quarter beat expectations on sales and per-share earnings, but Azenta still posted a loss at the net-margin level.

How did shares trade?

Azenta stock traded down $3.26 during Thursday’s midday session, reaching $45.64. Volume totaled 102,657 shares, below the average volume of 941,837.

The 50-day moving average (a rolling average of share prices over 50 trading days) stood at $35.98; the 200-day average was $28.51.

The 12-month range ran from a low of $15.93 to a high of $50.06. Azenta carried a $2.00 billion market capitalization, a negative P/E ratio (price-to-earnings valuation multiple) of -12.50 and a beta (share-price volatility relative to the market) of 1.47.

Takeaway: Shares fell sharply despite the earnings beat, and session volume remained below the stock’s average.

What did management forecast for fiscal 2027?

• Revenue: Management forecast $648 million to $660 million, above the roughly $632 million analyst consensus.
• Organic growth: Management expects 3% to 5%, excluding acquired operations.
• Adjusted EBITDA margin: Management expects about 200 to 250 basis points of expansion, equal to 2 to 2.5 percentage points, in adjusted earnings before interest, taxes, depreciation and amortization measured against revenue.

That combination points to management expecting stronger sales and improving profitability, matching the positive sentiment attached to the release.

Takeaway: Management expects fiscal 2027 to deliver above-consensus revenue and wider profitability margins.

What legal risk emerged?

Rosen Law Firm said it is investigating potential securities claims related to allegations that Azenta may have issued materially misleading business information. The notice adds legal uncertainty to the earnings and guidance picture.

The announcement is an investigation notice rather than a reported finding of wrongdoing, leaving the allegations at an unresolved stage.

Takeaway: Azenta faces an unresolved legal risk, but the notice does not establish wrongdoing.

How did analyst ratings change?

• Jefferies Financial Group: Raised its target from $44.00 to $52.00 on Wednesday and gave Azenta a “buy” rating.
• Wall Street Zen: Lowered Azenta from a buy rating to a “hold” in a Sunday, October 18 note.
• Needham & Company LLC: Lifted its target from $37.00 to $57.00 on Wednesday and gave the stock a buy rating.
• Weiss Ratings: Changed the rating from sell (e+) to sell (d-) in a Wednesday, August 26 note.

Four research analysts have Buy ratings, two have Hold ratings and one has a Sell rating. MarketBeat lists a Hold consensus and a $47.60 consensus price target.

The rating and target split shows that Azenta has not drawn a uniformly positive analyst view despite the above-consensus company forecast.

Takeaway: Two firms raised targets with buy ratings, while another moved to Hold and a fourth remained in the sell category.

What does Azenta do?

Azenta provides products and services for life-sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables and software used to track and manage samples.

Through GENEWIZ, Azenta provides genomic services, including sequencing and other genetic analysis, for researchers and organizations in the life-sciences and pharmaceutical industries.

Brooks Automation’s separation of its life-sciences business in 2021 created Azenta, which then adopted the Azenta name.

Takeaway: Azenta sells laboratory equipment, consumables and software while also providing genomic analysis services.

Azenta enters fiscal 2027 with above-consensus revenue guidance, but legal uncertainty and split analyst ratings remain unresolved.